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Abstract
Amyloid imaging is a valuable tool for research and diagnosis in dementing disorders. As positron 
emission tomography (PET) scanners have limited spatial resolution, measured signals are 
distorted by partial volume effects. Various techniques have been proposed for correcting partial 
volume effects, but there is no consensus as to whether these techniques are necessary in amyloid 
imaging, and, if so, how they should be implemented. We evaluated a two-component partial 
volume correction technique and a regional spread function technique using both simulated and 
human Pittsburgh compound B (PiB) PET imaging data. Both correction techniques compensated 
for partial volume effects and yielded improved detection of subtle changes in PiB retention. 
However, the regional spread function technique was more accurate in application to simulated 
data. Because PiB retention estimates depend on the correction technique, standardization is 
necessary to compare results across groups. Partial volume correction has sometimes been avoided 
because it increases the sensitivity to inaccuracy in image registration and segmentation. However, 
our results indicate that appropriate PVC may enhance our ability to detect changes in amyloid 
deposition.
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1. Introduction
Alzheimer’s disease (AD) is the most common form of dementia (Holtzman et al., 2011). 
The prevalence of AD is expected to increase dramatically worldwide over the next 50 years 
(Brookmeyer et al., 2007). It is well established that the pathological hallmarks of AD are 
amyloid plaques and neurofibrillary tangles (Holtzman et al., 2011). However, the 
underlying disease mechanisms remain under study. There currently are no proven disease-
modifying treatments (Aisen, 2009; Aisen et al., 2011; Doody et al., 2013; Huang and 
Mucke, 2012). Evidence suggests that pathological changes begin 10 to 20 years before the 
onset of clinical symptoms (Bateman et al., 2012; Morris and Price, 2001), which implies 
that successful treatment of AD may require early intervention. Hence, validated surrogate 
biomarkers for AD are needed for the design of therapeutic trials in asymptomatic 
individuals (Aisen, 2009; Aisen et al., 2011).
Positron emission tomography (PET) imaging of beta-amyloid (Aβ) plaques with tracers 
such as [11C]PiB (N-methyl-[11C]2-(4-methylaminophenyl)-6-hydroxybenzothiazole) 
(Klunk et al., 2004), [18F]florbetapir (Wong et al., 2010), [18F]florbetaben (Rowe et al., 
2008) and [18F]flutemetamol (Vandenberghe et al., 2010), enables in vivo measurement of 
fibrillar Aβ deposition, which provides an early indicator of AD pathology. Accurate 
quantification of Aβ burden is essential to better understand disease mechanisms, to develop 
early diagnostic techniques, and to identify suitable surrogate indicators for treatment 
monitoring.
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Partial volume effect (PVE) in positron emission tomography (PET) is a consequence of the 
poor spatial resolution of PET scanners, which typically is 5 to 6 mm full-width-half-max 
(FWHM). Because of PVE, the intensity of a particular voxel reflects the tracer 
concentration not only of the tissue within that voxel but also the surrounding area. In 
addition, PVE depends on the physical size and the shape of a region-of-interest (ROI) and 
its relative contrast with surrounding regions (Soret et al., 2007). When PET is used to 
measure amyloid burden, the impact of PVE becomes more complicated. Previous studies 
indicate that amyloid plaques primarily develop in the cortical and subcortical gray matter 
while the signal observed in white matter mainly comes from non-specific binding (Klunk et 
al., 2004). Non-specific PiB binding in white matter would not be a problem if the spatial 
resolution of PET permitted imaging gray matter without partial volume contributions from 
white matter. However, the resolution of PET is only ~5–6 mm. Hence, partial volume 
effect cannot be avoided. Without appropriate partial volume correction (PVC), 
quantification based on the raw PET images yields only a qualitative representation of the 
amyloid burden, not a quantitative one. Only when we apply appropriate PVC can we obtain 
quantitative measurement of amyloid burden. For a simple demonstration please refer to the 
supplementary material.
Currently, the approach to addressing PVE differs from one group to another and there is no 
consensus regarding whether correction for PVE is necessary and, if so, what type of 
correction should be used. We believe that this uncertainty is attributable to the limited 
understanding of the impact of PVE on quantitative amyloid imaging. In a recent 
longitudinal study (Villemagne et al., 2011), PVC increased the estimated regional standard 
uptake value ratios (SUVRs), but similar trends were obtained with and without PVC. The 
authors elected to not report PVC results to avoid potential inaccuracies resulting from 
segmentation errors (Villemagne et al., 2011). Other groups (Aizenstein et al., 2008; 
Lopresti et al., 2005; Lowe et al., 2009) use two-component PVC (Meltzer et al., 1996), 
which defines two types of tissue, i.e., brain and non-brain, and corrects for the 
underestimation of signal due to PVE caused by non-brain tissue. In a comparative study of 
two- vs. three-component (gray matter, white matter, and non-brain) PVC, it was concluded 
that the two-component method is better because it is less sensitive to registration and 
segmentation errors, although the three-component method is capable of more accurate 
absolute quantification (Meltzer et al., 1999). In contrast, a more recent paper (Thomas et 
al., 2011) advocates a region-based voxel-wise correction method to improve quantitative 
accuracy.
The goal of this study is to evaluate the impact of PVE on quantitative amyloid imaging in 
both cross sectional and longitudinal studies using simulated and human research data. In 
addition, we specifically examine the impact of individual variability in cortical thickness 
and brain atrophy upon quantification. We also investigate the test-retest reliability of PVC 
attributable to variability in registration and segmentation.
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2. Methods
2.1. Participants
Three cohorts were involved in this study (Table I). The first cohort included 16 participants 
recruited from the Knight Alzheimer Disease Research Center (ADRC). One of the 16 
participants had a CDR score of 0.5 (very mild dementia) while the CDR ratings for the rest 
were 0 (cognitively normal). This cohort was studied using a MRI test-retest (MRTRT) 
design to examine the sensitivity of PVC to uncertainty related to MRI images used as 
anatomical reference. Each participant in the MRTRT cohort underwent two separate MR 
scans on different days, using different MR sequences, and on different MR scanners, as 
described below in the imaging protocol. Another MRTRT experiment with anatomical MR 
acquired twice during the same imaging session was described in supplementary 2. The 
second cohort comprised 74 participants recruited at multiple sites as part of the 
international Dominantly Inherited Alzheimer Network (DIAN) initiative (Morris et al., 
2012). The DIAN cohort included only individuals known to carry an autosomal dominant 
mutation leading to early onset AD. The DIAN cohort was analyzed to investigate the 
impact of PVC on cross sectional studies. The estimated year-to-onset (EYO) was calculated 
for each individual in this cohort as the difference of the age of mutation carrier at the time 
of study and the parental age at onset (Bateman et al., 2012). EYO was used as the reference 
indicator of disease stage. The third cohort (LONG) included 42 participants from Knight 
ADRC, studied to investigate the impact of PVC on longitudinal studies. Six participants 
had a baseline CDR score of 0.5 while the rest had a CDR score of 0. Each LONG 
participant had a baseline visit and a follow-up visit at a mean interval of 2.2 years. The 
LONG cohort included only individuals with a baseline mean cortical binding potential 
(MCBP) greater than 0.06, as measured by PiB PET imaging (Mintun et al., 2006), to 
enhance the probability of observing an increase in amyloid deposition at the second visit 
(Sojkova et al., 2011). All three cohorts were independent and there was no overlap among 
the cohorts.
2.1.1 Ethics Statement—All assessment and imaging procedures were approved by 
Washington University’s (WashU) Human Research Protection Office. Written informed 
consent was obtained from all individuals or their care givers. Local institutional review 
boards also approved the collection of scans for archiving and future study at each non-
WashU study site.
2.2. Imaging
In all cohorts, PET imaging for quantitative estimation of amyloid deposition was performed 
using [11C]PiB, prepared according to the published protocol (Mathis et al., 2003). In the 
MRTRT cohort, dynamic PET imaging was conducted for one hour with a Biograph 40 
PET/CT scanner (Siemens Medical Solutions, Erlangen, Germany) in three-dimensional 
mode after intravenous administration of approximately 12mCi of PiB. The images were 
reconstructed on a 128 × 128 × 109 matrix (2.32 × 2.32 × 2.03 mm voxels) using filtered 
back-projection. Typical dynamic scans had 12 × 10-second frames, 3 × 60-second frames, 
and 11 × 5-minute frames. Anatomic MRI were acquired with an unaccelerated T1-weighted 
magnetization-prepared rapid gradient echo (MPRAGE) sequence (1 mm isotropic voxels) 
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using a Siemens Trio 3T scanner (Siemens Medical Solutions, Erlangen, Germany). In order 
to assess the sensitivity of PET quantification to variability in MRI acquisition, MRI 
processing (i.e. segmentation), and PET to MRI registration, a separate sagittal MPRAGE 
scan within 2 weeks from the PET/CT session was obtained on a Siemens Biograph mMR 
scanner (Siemens Medical Solutions, Erlangen, Germany) using an accelerated 3D 
Generalized Autocalibrating Partially Parallel Acquisition (GRAPPA) sequence with 1.1 × 
1.1 × 1.2 mm voxels.
In the DIAN cohort, structural MRI was performed using the Alzheimer’s Disease 
Neuroimaging Initiative (ADNI) protocol (Jack et al., 2010; Jack et al., 2008). A 3T scanner 
(Philips 3.0 T Achieva scanner (Philip Healthcare, Best, Netherlands) and a Siemens Trio 
3T scanner was used at all participating sites; the scanners were required to pass initial and 
regular follow-up quality control assessments to insure acquisition uniformity. The MRI 
protocol included an accelerated 3D GRAPPA sequence for MPRAGE acquisition same as 
the sequence used in the MRTRT study on the Biograph mMR. These images were screened 
for artifacts and protocol compliance by the ADNI MR Imaging Core before further 
analysis. For PET imaging, each site underwent an initial evaluation to insure compliance 
with the common PiB PET ADNI protocol. The PET scanners included in this study were 
EXACT 962 HR+ scanner (Siemens Medical Solutions, Erlangen, Germany) or a Biograph 
40 PET/CT scanner. Dynamic PiB PET acquisition consisted of either a 70-minute scan 
starting at injection or a 30-minute scan beginning 40 minutes post-injection. Only full 
dynamic scans (70-minute) were included in this study. Reconstruction was performed using 
filtered back-projection (128 × 128 × 63 matrix, 2.12 × 2.12 × 2.43 mm voxels on the HR+ 
scanner; 128 × 128 × 109 matrix, 2.32 × 2.32 × 2.03 mm voxels on the Biograph 40 
scanner).
The LONG cohort imaging protocol was similar to that of the MRTRT cohort. MPRAGE 
scans were acquired with a Siemens Trio 3T scanner. PiB PET was acquired on an EXACT 
962 HR+ scanner or a Biograph 40 PET/CT scanner. Each LONG participant contributed 
MRI and PET data acquired during initial and follow-up visits.
2.3. Image Analysis
FreeSurfer v5.1 (Martinos Center for Biomedical Imaging, Charlestown, Massachusetts, 
USA) (https://surfer.nmr.mgh.harvard.edu/fswiki) was used to automatically segment the 
brain into various regions (as defined in the wmparc.mgz file, please refer to FreeSurfer wiki 
for the output files from FreeSurfer analysis of the brain). Visual inspection of the 
automated segmentation results was performed for quality assurance purposes in all datasets. 
Corrections were made when necessary according to the FreeSurfer manual. Reconstructed 
PET images were smoothed to achieve a common spatial resolution of 8mm to minimize 
scanner differences (Joshi et al., 2009). Inter-frame motion correction for the dynamic PET 
images was performed using standard image registration techniques (Hajnal et al., 1995) 
implemented with in-house software (Eisenstein et al., 2012). PET-MR registration was 
performed using a vector-gradient algorithm (VGM) (Rowland et al., 2005) in a symmetric 
fashion (i.e. average transformation for PET->MR and inverse of MR->PET was used as the 
final transformation matrix). Regional time-activity curves for each ROI were extracted by 
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resampling the PET data to patient MR space. Regional binding potentials (BPND) were 
estimated using Logan graphical analysis (Logan et al., 1990) with the cerebellar cortex 
serving as the reference (Logan et al., 1996). BPND calculation was based on the first 60 
minutes of data. Although the brainstem has been used as the reference region in prior 
analyses of the DIAN cohort (Bateman et al., 2012), the cerebellar cortex was used here to 
obtain consistency across all three cohorts. Mean cortical binding potentials (MCBP) 
(Mintun et al., 2006) were calculated based on a selected set of cortical regions (Su et al., 
2013). The washout rate constant (k2) of the reference region (cerebellum) was set to 0.16/
minute (Mintun et al., 2006). The impact of PVC technique was assessed using BPND 
measures evaluated in three regions of interest. To assess the impact of different PVC 
techniques, (i) MCBP (Mintun et al., 2006) was examined to assess global effects; (ii) 
precuneus was chosen as representative cortical region with known high predisposition to 
amyloid deposition (Mintun et al., 2006); and (iii) putamen was chosen as an example of a 
subcortical region that can have elevated PiB uptake in AD (Su et al., 2013).
2.4. Partial Volume Correction
Two PVC methods were compared in this study. The first method is the two-component 
(PVC2C) approach (Meltzer et al., 1996), which is most widely represented in amyloid 
imaging literature (Aizenstein et al., 2008; Lopresti et al., 2005; Lowe et al., 2009; Rosario 
et al., 2011). In our implementation, a brain tissue mask is generated based on FreeSurfer 
segmentation, a CSF dilution factor is calculated for each region, and the raw time activity 
curve for each region is corrected by this dilution factor before BPND is calculated. The 
second method is based on computation of the regional spread function (RSF) (Rousset et 
al., 2008; Rousset et al., 1998), which has also been extensively applied in PET imaging 
analysis (Kim et al., 2013; Kuhn et al., 2014; Le Pogam et al., 2011). Our implementation of 
RSF PVC also included additional ROIs outside the brain (hence, not defined by FreeSurfer) 
to account for tracer uptake in non-brain tissue. The combined ROI set was used as the basis 
for RSF PVC, in which a matrix of regional transfer coefficients (Rousset et al., 1998) was 
calculated using the ROI map and an 8-mm FWHM Gaussian smoothing kernel. Corrected 
ROI values were calculated by solving a linear system relating regional transfer coefficients 
to observed regional values (Eq. 1):
(1)
where, O is a column vector corresponds to the observed regional mean intensity for n ROIs, 
and T is a column vector representing the true intensity values in regions 1 to n. Each 
element (wij) in the matrix W on the right hand side of Eq. 1 is a regional transfer coefficient 
that determines the signal spillover from region i to region j. In other words, PVC2C 
performs the correction by scaling the regional measurement by a pre-computed correction 
factor which only depends on the scanner point spread function and relative location of the 
voxel/ROI to the boundary. These correction factors ignore gray-white contrast and 
therefore remain constant throughout a dynamic scan. On the other hand, after RSF PVC 
correction, the corrected/uncorrected ratio takes into account the local contrast which 
changes over time. Because of this difference the PVC2C only changes the magnitude of a 
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TAC while the RSF-based PVC restore both the shape and magnitude of a TAC, two 
attributes that ultimately determine the estimated binding parameters at each voxel or region.
2.5. Simulation study
Simulation was conducted to evaluate the impact of brain atrophy and partial volume effects 
on amyloid imaging quantification. The procedure for generating simulated PiB PET 
imaging data was similar to that previously described (Su and Shoghi, 2008) and is 
summarized in Figure 1. MR images of six participants with different cortical thicknesses 
(2.3–2.8mm), as measured using FreeSurfer, were chosen from our Knight ADRC cohort 
(see Fig 2A and 2B as an example). To generate simulated dynamic PET data, each region 
was assigned a time-activity curve (TAC) similar to Fig 2C. These TACs were obtained 
from actual patient data with 5 different level of amyloid load as measured by PiB PET 
imaging. After assignment of regional TACs, an example frame was shown in Fig. 2D. An 
8mm FWHM Gaussian kernel was used to smooth the simulated data (Fig. 2E). Noise was 
added to the PET data in sinogram space (Su and Shoghi, 2008). Poisson distributed noise 
was added and the magnitude of the noise is controlled by the counts, which was calibrated 
to the typical counting statistics of our patient imaging data. The sinogram were then 
reconstructed using filtered back-projection (FBP) technique. FBP based reconstruction was 
also performed on the noiseless version of the sinogram data and the difference between the 
reconstructed images created with and without sinogram noise was calculated as the noise 
image. The noise image is added back to the original simulated noiseless imaging data (Fig. 
2E) to generate the final simulated PiB PET data (Fig. 2F). This procedure is to ensure the 
simulated PET image indeed has 8mm resolution while also has realistic imaging noise. A 
total of 30 simulated dynamic PET datasets were created for different combinations of MR 
and PET. To simulate longitudinal studies, a follow up MRI scan more than a year apart of 
the same participant from three of the six subjects was also used to create additional 
simulations to evaluate the impact of atrophy.
2.6. MR Test-Retest Variability
One concern in applying MRI-based PVC techniques in quantitative PET is that variability 
related to MRI acquisition and processing may propagate to the final correction and increase 
noise (Frouin et al., 2002; Zaidi et al., 2006). To examine this issue, a MR test-retest study 
was performed in the MRTRT cohort, in which each participant underwent two separate 
MPRAGE scanning using different scanners, MR sequences, and on different days. 
Quantification with and without PVC was performed using these two MPRAGE images 
with the same PET scan. Each image was independently segmented by FreeSurfer and co-
registered with the PiB PET. A mean test-retest variability measurement was calculated for 
each region with and without PVC according to Eq. 2:
(2)
where N is the total number of participants (16); i indexes participant; BPNDi1 was 
calculated based on MPRAGE acquired on the Trio scanner; and BPNDi2 was calculated 
based on MPRAGE acquired on the mMR scanner. In addition, a volumetric variability 
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measurement was also calculated for each region based on the repeated MPRAGE and 
FreeSurfer outputs following Eq. 3:
(3)
where VOLi1 and VOLi2 are the volumes in each FreeSurfer region obtained from Trio and 
mMR scans respectively, indexed by participant (i).
3. Results
3.1. Simulation Study
The simulation study demonstrated that, without PVC, lower cortical thicknesses led to a 
greater underestimation of the binding potential for both global (MCBP) and local 
measurements (Fig. 2). This outcome is expected on the basis of PVE principles. The 
estimated binding potential without PVC positively correlated with cortical thickness. The 
slope of the linear relationship, as calculated by linear regression of BPND vs. thickness, 
increased with increasing amyloid load. For each millimeter loss in cortical thickness, the 
estimated MCBP was reduced by 0.11 to 0.24, depending on the underlying amyloid load. 
The estimated precuneus binding potential was reduced by 0.21 to 0.43 for each mm loss in 
precuneus thickness. Both PVC techniques corrected the estimated binding potentials so that 
BPND remained constant across different cortical thicknesses. However, the PVC2C method 
differentially underestimated the “true” binding potential depending on amyloid burden. 
This underestimation was minimal at low amyloid load and large at high amyloid load. The 
impact of PVE was greater in high Aβ regions such as the precuneus as compared to global 
measures.
Similar partial volume effect was observed in the simulated longitudinal data (Fig. 3). PiB 
binding was modeled as constant over both time points. In general, without PVC, the 
estimated binding potentials decreased with decreasing cortical thickness and this effect was 
more pronounced at higher amyloid loads. Underestimation of MCBP ranged from 0.14 per 
millimeter decrease in cortical thickness at low amyloid load to 0.36 per millimeter decrease 
in cortical thickness at high amyloid load. The slope of decrease for the precuneus BPND 
ranged from 0.27 per millimeter decrease in cortical thickness to 0.61 per millimeter 
decrease in cortical thickness. Therefore, it is possible to observe false decreases in BPND if 
PVC is not performed when atrophy occurs during longitudinal studies. Both PVC 
techniques reduced the impact of PVE but the RSF technique was more stable.
3.2. MR Test-Retest Variability
The MRTRT dataset showed low variability in estimated BPND (Table II). For MCBP, the 
average RBP% was 1.57±1.01% without PVC, 1.41±2.13% using PVC2C and 2.09±1.78% 
using RSF PVC. In comparison, the variability for FreeSurfer ROI volumes was greater than 
~2% or more for all regions.
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3.3. Cross-sectional Patient Study
Partial volume correction generally resulted in higher estimated binding potentials in cortical 
regions (Fig. 4). In left precuneus, the estimated PiB binding was approximately 2.2 times 
higher on average using the RSF method than without PVC and ~1.2 times higher on 
average using PVC2C. In the putamen, PVC2C resulted in lower PiB binding estimation 
(0.45 times the uncorrected version for left putamen); and RSF resulted in slightly higher 
PiB binding estimation (1.1 times the uncorrected values for left putamen).
Figure 5 shows the relation between PiB binding potentials estimated with PVC (two 
methods) vs. without PVC. These relations are remarkably linear (r = 0.99) across 
participants with varying levels of Aβ accumulation. However, the slope and intercept of 
these linear relationships based on particular brain regions are strongly regionally specific.
3.4. Longitudinal Study
The results of the longitudinal study are summarized in Table III. On average, the left 
precuneus lost volume at a rate of 0.04 cc/year (0.42%/year); and the left putamen lost 
volume at a rate of 0.05 cc/year (0.93%/year). Without PVC, BPND increased at a rate of 
0.021/year (1.57%/year) in left precuneus and increased at 0.012/year (0.87%/year) in left 
putamen. With RSF PVC, BPND increased at a rate of 0.077/year (4.23%/year) in the left 
precuneus and increased 0.033/year (2.26%/year) in the left putamen. The PVC2C results 
fell in between the uncorrected and the RSF PVC measurements. The significance of 
longitudinal difference in BPND appears to be enhanced with RSF PVC, as manifested by 
more significant p-values in a two-tailed paired t-test. The p-value changed only moderately 
when PVC2C was applied. Without PVC, decreased MCBP was observed in 9 participants 
and decreased precuneus BPND was observed in 11. When RSF PVC was performed, 4 of 
the 9 decreases in MCBP reversed, and 7 of the 11 decreases in precuneus BPND reversed. 
This indicates the observed decrease in BPND without PVC maybe an artifact of brain 
atrophy.
4. Discussion
We compared two partial volume correction techniques in the context of quantitative PET 
amyloid imaging using both simulated and participant data. Both PVC methods reduced bias 
caused by partial volume effects. RSF PVC yielded more accurate binding potential 
estimations based on the simulation study. The simulation (forward model) accounted for 
time activity curves in gray matter, white matter, and non-brain regions. Thus, the forward 
model can be viewed as an expansion of three-component approach (Meltzer et al., 1999) 
except that each ROI was independently assigned its own TAC. That RSF PVC performed 
best with the simulations is expected because it effectively inverts the forward model except 
for the addition of noise. The RSF technique assumes within region homogeneity in tracer 
uptake, while in reality the variability may not follow anatomical driven ROI definition. 
Other PVC technique such as the region-based (RBV) correction (Thomas et al., 2011) or 
the Gaussian mixture deconvolution (GMD) (Bousse et al., 2012) are voxel-wise methods. 
Such methods potentially preserve greater detail at the voxel level but should give similar 
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results at regional level. Further investigation is needed to understand the robustness and 
accuracy of these techniques.
It should be pointed out that while we adopted the resolution normalization technique (Joshi 
et al., 2009) to achieve approximately 8mm in spatial resolution across different scanners, 
the scanner resolution is inherently spatially varying, and our normalization filtering cannot 
fully account for this which may lead to subtle differences between scanners. This can 
potentially be improved by measuring the individual scanner point spread function using 
physical phantoms and performing PVC based on that. It should also be pointed out that our 
imaging analysis procedure assumes the different MR scanners have the same spatial 
resolution, while in fact there are small between scanner differences in scanner resolution, 
these factors may further complicate the PET quantification.
The objective of PVC is to reduce bias in point estimates of gray matter Aβ burden. The cost 
of PVC is that it can amplify noise in PET quantification attributable to PET to MR 
registration and segmentation of anatomical MR data (Meltzer et al., 1999). We examined 
this issue using an MPRAGE test-retest design and confirmed the general principle. The 
observed change in binding potential (BPND) estimates attributable to the variability in 
MPRAGE registration and segmentation was less than 3% with and without PVC. In 
comparison, full test-retest BPND variability has been reported to be approximately 5% 
(Lopresti et al., 2005). It has been demonstrated that differences in imaging sequence, 
scanner, and magnet strength can cause discrepancy in brain segmentation (Han et al., 2006; 
Jovicich et al., 2009). It is important to keep this in mind in study design to minimize 
possible complications. As demonstrated in another MR test-retest study using repeated 
MPRAGE scans acquired within the same imaging session using the same MR sequence the 
MR test-retest variability is substantially smaller at less than 1% (Supplementary 2), which 
gives us an idea of how much improvements we can possibly achieve by limiting the 
variability in MR acquisition.
The impact of PVC to the estimated BPND is highly regional specific as demonstrated by the 
relationship between BPND and EYO (Fig. 4) and corrected vs. uncorrected BPND (Fig. 5). 
This can be explained by examining the regional TACs with and without PVC, as shown in 
lower panel of Fig. 4. A substantially greater intensity value for the precuneus cortex and a 
slightly lower intensity value for the cerebellar cortex (the reference) resulted in a large 
increase in estimated BPND using RSF PVC. On the other hand, PVC2C resulted in higher 
ROI values for both precuneus and cerebellar cortex, hence, only a slightly increased BPND. 
For a subcortical region such as the putamen, neither PVC technique significantly changed 
PET image intensity values; altered BPND values were mainly attributable to differences in 
the reference region TAC with and without PVC. Increased cerebellar cortex intensity with 
PVC2C resulted in lower BPND of putamen; slightly lower cerebellar cortex intensity with 
RSF PVC resulted in slightly higher BPND. These regionally specific constants reflect the 
interaction between limited PET resolution and varying levels of non-specific vs. specific 
tracer binding as well as ROI shape. Thus, quantitative PiB imaging strongly depends on use 
of PVC and type of PVC.
Su et al. Page 10
Neuroimage. Author manuscript; available in PMC 2016 February 15.
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
The high levels of linear correlation between BPND with and without PVC in the cross 
sectional study (Fig. 5) may seem counter-intuitive. In theory, as the disease progresses, 
more severe atrophy should result in a larger impact of PVE, as demonstrated in Fig. 4, 
therefore a non-linear relationship would be expected. This may because our participants are 
either asymptomatic or early symptomatic AD patients and the amount of atrophy is 
relatively small. In addition, people with high BPND do not necessarily have more atrophy 
because of the high variability of amyloid deposition at a given cortical thickness level. PVC 
is expected to be more critical for measuring amyloid deposition in brain with more severe 
atrophy.
Based on our longitudinal study, the annual rate of amyloid accumulation (signal) was 3.4 
times greater when RSF PVC is applied and 1.59 times greater with PVC2C in comparison 
to the values without PVC (Table III), while the standard deviation in the rate of amyloid 
accumulation (noise) was only 1.82 and 1.24 times greater with RSF PVC and PVC2C 
respectively. In addition, the observed difference in amyloid load between the baseline and 
follow-up study in the LONG cohort was more significant (smaller p values) when PVC was 
applied, especially with the RSF PVC technique. Therefore, we believe PVC will improve 
our ability to detect amyloid load change in longitudinal studies.
Finally, comparisons of amyloid load across different regions within the same subject would 
be difficult without PVC, because of the differential impact of partial volume effects on 
regions of different size and shape as shown by the regionally different slopes in Fig. 5. Our 
study demonstrates that, if the goal of amyloid imaging is to obtain a single numerical 
measurement of amyloid load, for example to provide diagnostic information, then PVC 
only provide minor additional information because of the highly linear relationship between 
the uncorrected and corrected binding potentials. However, if the goal of amyloid imaging is 
to better understand the disease mechanism, to assess the regional differences in the amyloid 
plaque pathology, then PVC is an important step.
5. Conclusion
The impact of partial volume correction (PVC) on quantitative amyloid imaging was 
investigated using both simulated and participant data. PVC compensates for partial volume 
effects, which, if uncorrected, lead to underestimation of amyloid load. A theoretical cost of 
PVC is that it increases the noise of amyloid load measurement due to uncertainties in image 
registration and segmentation. However, our data demonstrate that PVC improved the 
sensitivity of detecting subtle changes in amyloid binding, especially when using the RSF 
technique. We therefore recommend PVC be performed in all amyloid imaging studies, 
although standardization of the PVC technique is needed to compare studies across different 
groups.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Highlights
• Two PVC techniques were examined for quantification of PiB imaging data.
• Performance was compared using simulated, MR test-retest, cross-sectional and 
longitudinal data.
• Both PVC techniques were able to compensate for partial volume effects.
• Regional Spread Function technique was able to generate more accurate results.
• PVC improves the capability in detecting subtle changes in PiB retention.
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Figure 1. 
Demonstration of the simulation procedure. A) Example MR data. B) FreeSurfer 
segmentation of the MR data. A time-activity curve (TAC) was assigned to each ROI. C) 
Example regional TAC D) Example frame of simulated data after assigning a TAC to each 
region. E) PET frame smoothed to PET resolution. F) Final simulated dynamic PET frame 
including noise.
Su et al. Page 17
Neuroimage. Author manuscript; available in PMC 2016 February 15.
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
Figure 2. 
Estimated binding potentials with and without partial volume correction for simulations 
created with different cortical thickness and amyloid load.
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Figure 3. 
Impact of partial volume effects to binding potential estimation due to longitudinal changes 
in cortical thickness based on the simulation study.
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Figure 4. 
Trajectories of PiB binding estimated with cross sectional first-degree LOESS curves with 
and without PVC (top row). And regional time-activity curve with and without PVC for an 
example subject (bottom row).
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Figure 5. 
Regional binding potentials with and without PVC. Although for individual regions, the 
PVC corrected BPND were highly correlated with the uncorrected version, the slope of the 
linear relationship varies from one region to another. On average, the estimaged BPND 
increased 41±33%, 8±14%, and 31±22% for left precuneus, left putamen and MCBP 
respectively when RSF PVC is applied; the estimated BPND increased 7±8% for left 
precuneus, decreased 17±2% for left putamen, and increased 12±5% for MCBP when 
PVC2C is applied. The percent change is calculated as (BPPVC−BPraw)/(1+BPraw)×100%.
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Table I
Demographics for this study
Cohort MRTRT DIAN LONG
N 16 74 42
Age (SD) years 63.0(9.0) 39.1(11.3) 70.7(5.5)
EYO (SD) years - −8.1(11.1) -
Education (SD) years 15.5(2.4) 14.4(2.5) 15.6(2.3)
Male (%) 8(50.0) 36(48.6) 16(38.1)
CDR>0 (%) 1(6.3) 21(28.4) 6(14.3)
APOE4+ (%) 3(19.7) 30(40.5) 22(52.4)
PET interval (SD) years - - 2.2(0.85)
MRTRT (MR test-retest); DIAN (Dominantly Inherited Alzheimer’s Network); LONG (longitudinal cohort from Knight ADRC); CDR: Clinical 
Demential Rating; APOE4+: carrier of at least one copy of E4 version of apolipoprotein gene; EYO; estimaged year to onset.
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Table III
Longitudinal study results (mean±SD where applicable).
left precuneus left putamen MC CALL
Baseline Vol (cc) 8.5±1.2 5.0±0.7 143.4±15.0 411.8±42.5
ΔVol/year (cc/year) −0.04±0.15 −0.05±0.15 −0.83±1.91 −2.08±5.35
ΔVol%/year (%/year) −0.42±1.82 −0.93±3.17 −0.58±1.31 −0.49±1.30
p-value 7.9E-02 3.6E-02 6.0E-03 1.1E-02
Baseline BPND 0.42±0.28 0.46±0.20 0.32±0.26 0.26±0.21
ΔBPND/year (/year) 0.021±0.04 0.012±0.07 0.016±0.03 0.009±0.03
ΔBP%/year (/year) 1.57±2.29 0.87±3.70 1.28±1.88 0.78±1.73
p-value 6.5E-05 6.1E-02 8.0E-05 2.7E-03
Baseline BPND (PVC2C) 0.50±0.32 0.19±0.16 0.50±0.32 0.42±0.25
ΔBPND/year (PVC2C) (/year) 0.028±0.05 0.010±0.05 0.025±0.4 0.015±0.03
ΔBP%/year (PVC2C) (/year) 1.88±2.38 0.83±3.57 1.71±1.99 1.12±1.66
p-value 1.7E-05 9.5E-02 1.0E-05 1.4E-04
Baseline BPND (RSF) 0.85±0.66 0.39±0.28 0.64±0.55 0.52±0.43
ΔBPND/year (RSF) (/year) 0.077±0.08 0.033±0.11 0.054±0.06 0.036±0.05
ΔBP%/year (RSF) (/year) 4.23±3.75 2.26±6.03 3.41±2.90 2.46±2.46
p-value 1.3E-07 5.6E-03 5.9E-08 1.3E-06
MC: contains regions that went into the calculation of MCBP using a FreeSurfer based approach (Su et al., 2013) including ctx-lateralorbitofrontal, 
ctx-medialorbitofrontal, ctx-precuneus, ctx-rostralmiddlefrontal, ctx-superiorfrontal, ctx-superiortemporal, and ctx-middletemporal; CALL: all 
cortical gray matter region; p-value refers to two-tailed paired student t-test result between the follow up visit and the baseline visit; ΔBP% was 
calculated according to Eq. 1 and ΔVOL% was calculated according to Eq. 2.
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